Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine for Post-COVID-19 Fatigue
NCT05667077Phase 2Unknown
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Dec 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of amantadine in Post COVID-19 Syndrome (PCS) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Fatigue Severity Scale at 2 weeks and Visual Analog Fatigue Scale at 2 weeks. Status: unknown.
02
Drugs
amantadine
03
Conditions
Post COVID-19 Syndrome (PCS)
Beyond the preview
Go deeper on NCT05667077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667077.